{"disease":{"id":"follicular-lymphoma-fl","name":"follicular lymphoma fl"},"drugs":{"marketed":[{"drug_id":"zanubrutinib","indication_name":"Follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory advanced follicular lymphoma (FL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06091254","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":822,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06097364","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03460977","title":"A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":453,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03768505","title":"Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":169,"lead_sponsor_name":"MEI Pharma, Inc.","has_results":true},{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT07197307","title":"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Universität Münster","has_results":false},{"nct_id":"NCT05888493","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03265158","title":"Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0","phase":"","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT03547115","title":"A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"MEI Pharma, Inc.","has_results":false},{"nct_id":"NCT04745832","title":"Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"MEI Pharma, Inc.","has_results":true},{"nct_id":"NCT02875548","title":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT06757894","title":"Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04537715","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT07360288","title":"Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT06959732","title":"Zanubrutinib Combined With G-CVP in Previously Untreated FL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07077512","title":"Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT07168486","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT07412405","title":"This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"GUSTAVO SALGUERO","has_results":false},{"nct_id":"NCT05507541","title":"TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03571828","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05720052","title":"A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"MingSight Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT07168291","title":"Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":3,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04796922","title":"To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05619367","title":"A Compassionate Use (CU) Program of Odronextamab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":33},"guidelines":[{"drug_id":"rituximab","guideline_body":"FDA label","recommendation":"RITUXAN HYCELA is indicated for relapsed or refractory follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first-line chemotherapy, and as single-agent maintenance therapy in patients achieving a complete or partial response to rituximab in combination with chemotherapy; non-progressing (including stable disease) follicular lymphoma as a single agent after first-line CVP chemotherapy.","line_of_therapy":"2L|1L|maintenance","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}